Original Article



Outcomes of an ambulatory care pharmacist-led antimicrobial stewardship program within a family medicine resident clinic

Lindsey R. Westerhof PharmD, BCACP¹ ^(b), Lisa E. Dumkow PharmD, BCIDP¹, Tarajo L. Hanrahan MD²,

Samantha V. McPharlin MD² and Nnaemeka E. Egwuatu MD, MPH³

¹Mercy Health Saint Mary's Health System, Department of Pharmacy, Grand Rapids, Michigan, ²Mercy Health Saint Mary's Health System, Department of Family Medicine, Residency Center Grand Rapids, Michigan and ³Mercy Health Saint Mary's Health System, Department of Infectious Diseases, Grand Rapids, Michigan

Abstract

Objective: To determine whether an ambulatory care pharmacist (AMCP)-led intervention improved outpatient antibiotic prescribing in a family medicine residency clinic (FMRC) for upper respiratory tract infections (URIs), urinary tract infections (UTIs), and skin and soft-tissue infections (SSTIs).

Design: Retrospective, quasi-experimental study comparing guideline-concordant antibiotic prescribing before and after an antimicrobial stewardship program (ASP) intervention.

Setting: Family medicine residency clinic affiliated with a community teaching hospital.

Participants: Adult and pediatric patients prescribed antibiotics for URI, UTI, or SSTI between November 1, 2017, and April 31, 2018 (pre-ASP group), or October 1, 2018, and March 31, 2019 (ASP group), were eligible for inclusion.

Methods: The health-system ASP physician and pharmacist provided live education and pocket cards to FMRC staff with local guidelines as a quick reference. Audit with feedback was delivered every other week by the clinic's AMCP. Guideline-concordance was determined based on the institution's outpatient ASP guidelines.

Results: Overall, 525 antibiotic prescriptions were audited (pre-ASP n = 90 and ASP n = 435). Total guideline-concordant antibiotic prescribing at baseline was 38.9% (URI, 53.3%; SSTI, 16.7%; UTI, 46.7%) and improved across all 3 infection types to 57.9% (URI, 61.2%; SSTI, 57.6%; UTI, 53.5%; P = .001). Significant improvements were seen in guideline-concordant antibiotic selection (68.9% vs 80.2%; P = .018), dose (76.7% vs 86.2%; P = .023), and duration of therapy (73.3% vs 86.2%; P = .02).

Conclusions: An AMCP-led outpatient ASP intervention significantly improved guideline-concordant antibiotic prescribing for common infections within a FMRC.

(Received 7 August 2020; accepted 8 October 2020; electronically published 13 November 2020)

With almost 250 million antibiotic prescriptions issued annually, outpatient antimicrobial prescribing accounts for the majority of antibiotic use within the United States.¹ Unfortunately, it is estimated that 30%–50% of these antibiotics are prescribed unnecessarily or inappropriately, meaning that even when antibiotics are needed, they are not optimized by drug chosen, dose, or duration of therapy.² The goal of the US National Action Plan was to reduce inappropriate antibiotic use by 50% in the outpatient setting

Author for correspondence: Lindsey R. Westerhof, E-mail: lindsey.westerhof@mercyhealth.com

PREVIOUS PRESENTATION: Preliminary data were presented at the Michigan Family Medicine Research Day Conference On May 23, 2019, in Howell, Michigan, and an abstract of this work was accepted as a poster presentation at ECCMID 2020 on April 20, 2020, in Paris, France; it was published online only because the conference was canceled due to COVID-19.

Cite this article: Westerhof LR, et al. (2021). Outcomes of an ambulatory care pharmacist-led antimicrobial stewardship program within a family medicine resident clinic. Infection Control & Hospital Epidemiology, 42: 715–721, https://doi.org/10.1017/ ice.2020.1275

between 2015 and 2020, but prescribing trends have remained relatively stagnant as of 2018.^{3,4}

Antimicrobial stewardship programs (ASPs) consisting of coordinated efforts to improve antimicrobial prescribing have consistently demonstrated improved antibiotic utilization and patient outcomes.⁵ Although most of these programs have traditionally focused on inpatient prescribing, the Centers for Disease Control and Prevention (CDC) has recently developed guidelines for implementing outpatient ASPs, noting the critical importance of establishing these programs where most antibiotics are prescribed. More than 35% of oral antibiotics are prescribed by primary-care physicians.¹ These guidelines provide a framework for ASP implementation, including establishing program leadership, provider education, and interventions such as prescription audit with feedback.⁶

Despite guidance from the CDC to establish outpatient ASPs, literature examining successful ASP interventions within primary care sites is limited; most studies target upper respiratory tract infections (URIs).⁷⁻¹² Furthermore, few efforts have targeted

CrossMark

© The Author(s), 2020. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

medical residents, an important target for ASPs in establishing good habits for antibiotic prescribing.^{13–15} Although infectious diseases (ID) practitioners typically serve as ASP leaders in inpatient settings, this resource may be scarce in the outpatient setting. Ambulatory care pharmacists (AMCPs) working within primary-care practice sites may serve a critical role as stewardship collaborators and leaders in the outpatient setting; they have established relationships with the provider team and skills needed to identify problematic trends in antimicrobial use and to provide active intervention. The purpose of this study was to determine whether a multifaceted ASP intervention using education, guideline-distribution, and AMCP-led audit with feedback improved antibiotic prescribing in a family medicine resident clinic for common infections, including URIs, skin and soft-tissue (SSTIs), and urinary tract infections (UTIs).

Methods

Study site and antimicrobial stewardship program

This study was conducted at a single primary-care office in Grand Rapids, Michigan. The practice site serves as an ACGMEaccredited physician training and practice site for 30 family medicine resident physicians (10 per class) and 4 attending physicians. The office is also staffed with 1.0 full-time equivalent (FTE) split between 2 AMCPs. They spend ~0.5 FTE devoted to chronic disease state management and resident teaching within the primary-care office and the remaining 0.5 FTE teaching and precepting at the college of pharmacy. Beginning in October 2018, one of the AMCP's time was restructured to devote 0.1 FTE (1 day every other week) to implementing antimicrobial audit and feedback within the family medicine resident clinic (FMRC). Two second-year medical residents served as physician champions to foster support and collaboration with the AMCP and to work with the prescriber team to assess preferred methods of feedback communication.

The FMRC offers comprehensive care for both adults and children and is affiliated with Mercy Health Saint Mary's Hospital. Mercy Health Physicians Partners has 22 primary-care locations within the Grand Rapids metropolitan area; however, only 4 offices currently have an AMCP. The primary-care offices are supported by the health system's ASP, which is directed by an ID pharmacist (1.0 FTE) and supported by an ID physician (0.1 FTE). The stewardship program publishes an outpatient antibiogram annually as well as empiric therapy guidelines that provide treatment recommendations for antimicrobial therapy based on national guidelines, current best practices, and local susceptibility patterns. Prior to the initiation of the intervention in the FMRC, the ASP team had piloted an audit-and-feedback program within a single, nonteaching, family medicine clinic staffed with a full-time AMCP (1 FTE).¹⁶ The FMRC intervention was modeled after this pilot-site program that had targeted both URI and UTI prescribing. The ID pharmacist and physician mentored the AMCP to provide baseline education regarding local treatment recommendations and a model for provider feedback.

Study design

This investigation was a retrospective quasi-experimental study conducted to evaluate the outcomes of a multifaceted outpatient ASP intervention including education, guideline dissemination, and pharmacist-led audit and feedback. Two time periods were designated for comparison. Antibiotic prescriptions issued between November 1, 2017, and April 31, 2018, were eligible for inclusion in the preintervention period (pre-ASP group), while the postintervention period included all antibiotic prescriptions issued between October 1, 2018, and March 30, 2019 (ASP group). Prescribing data were generated electronically from the Athenahealth electronic health record (EHR) system. The EHR required each antibiotic prescription to be linked to a diagnosis code, and categorization of the antibiotics was consistent through the entire study period.

Baseline prescribing habits

To identify baseline prescribing practices, a report was generated from the EHR of all antibiotics prescribed during the 6-month preintervention period. This report was reviewed by the AMCP, and antibiotics were assigned to one of several indication categories, based on the diagnosis code, to determine the 3 most common indications for which the providers prescribed antibiotics. The 3 most common indications identified were URIs, SSTIs, and UTIs. Using this same data set and the Excel random-number generator (Microsoft, Redmond, WA), the AMCP performed an audit of a random sampling of 30 prescriptions from these 3 indications to determine baseline guideline-concordant prescribing, educational needs, and targets for improved prescribing during the intervention period.

Provider and staff education

The ID pharmacist, AMCP, and ID physician provided a live education session to all resident clinic providers prior to the intervention period. The session reviewed baseline prescribing data, including areas for improvement, local resistance trends, and a review of the institutional guidelines. This presentation also emphasized the importance of not prescribing antibiotics for viral infections based on symptom persistence and severity. Providers were given pocket cards of the institutional guidelines for URIs, SSTIs, and UTIs as a quick, abbreviated reference tool (Fig. 1).

Audit and feedback of prescribing practices

The AMCP was responsible for every-other-week audit and feedback for all prescribed antibiotics for URIs, SSTIs, and UTIs, beginning October 1, 2018, and continuing for 6 months through March 31, 2019. The AMCP accessed the EHR antibiotic report and performed indication categorization in the same way as the baseline data. Prescriptions for both adult and pediatric patients were eligible. Feedback was provided electronically through an EHR messaging system that was not part of the patient record. Feedback included recommendations regarding treatment indication and antibiotic drug selection, dose (including both strength and frequency of administration), and duration of therapy based on the institutional guidelines. Providers were also given positive feedback for other habits such as utilizing watch-and-wait prior to prescribing an antibiotic or prescribing a topical dosage form over an oral antibiotic when indicated. Feedback was not provided in any quantitative way or with peer comparison. The electronic message condensed feedback from all antibiotics prescribed during a 2-week window and utilized language that was supportive and encouraging and referenced the particular case using a patient medical record number (MRN). An example of written feedback is provided in Figure 2.

Treatment of Pediatric Outpatients at Mercy Health Saint Mary's

Pathogens	First-Line	Severe beta-lactam allergy	Duration
Virus S. pneumoniae, H. influenza, M. catarrhalis **NOTE: Bacterial etiology should only be considered if: Persistent symptoms without improvement of nasai discharge or daytime cough >10 days Severe symptoms: fever 239°C, purulent nasail discharge for at least 3 consecutive days	Amoxicillin suspension 80–90 mg/kg per day f divided in 2 doses (Maximum 500 mg/dose) OR A moxicillin/clavulanate 80–90 mg/kg per day P divided in 2 doses (Max: 875 mg per dose	Cefdinir 14 mg/kg/day PO in 1 or 2 divided doses (Maximum 300 mg/dose or 600mg/day) OR Trimethoprim/ sulfamethoxazole 8 mg TMP/kg/day PO divided in 2 doses	7 - 10 day
Otitis Media			
Pathogens S. pneumoniae, H. influenza, M. catarrhalis, virus ** Watch and wait x 48–72 hr is recommended for children is recommended for children greater than 6 months with unilateral AOM without otalgia	Amoxicillin suspension S0-90 mg/kg per day PO divided in 2 doses (Maximum S000mg/dose) OR Amoxicillin/clavulanat e 80-90 mg/kg per day PO divided in 2 doses (Max: 875 mg per dose)	Cefdinir 14 mg/kg/day PO in 1 or 2 divided doses (Maximum 300 mg/dose or 600mg/day) OR Batcrim (TMP-SMX) 8 mg TMP/kg/day PO divided in 2 doses	7 - 10 days
Urinary Tract Infect Pathogens Fire	tion st-Line	Severe beta-lactam allergy	Duration
E. coli, Klebsiella, • Proteus	Cephalexin 25 mg/kg/day PO divided in 2 doses (Maximum 500 mg/dose q 12 h)	 Bactrim (TMP- SMX) (age>2 months) 8 mg TMP/kg/day PO divided in 2 doses 	 UTI: 7 days Pyelonephritis: 10 – 14 days

Pathogens	First-Line	Severe beta- lactam allergy	Duration of Therapy
Virus S. pneumoniae, H. influenza, M. catarrhalis	 Amoxicillin/ clavulanate 875/125 mg PO q 12 h OR Cefuroxime 500 mg PO q 12 h 	 Doxycycline 100 mg PO q12h 	5 – 7 days
Bronchitis/AE-Co	DPD		
Pathogens	First-Line	Second-line	Duration
H. influenzae, S. pneumoniae, M catarrhalis	 Astronycin 500 + mg PO x 1 day, then 250 mg days 2 - 5 	Ceruroxime 500 mg PO q 12 h Amoxicillin/ clavulanate 875/125 mg PO q 12 h	5 days
Pathogens	First-Line	Second-line	Duration
Pathogens Group A streptococcus	First-Line Penicillin 500 mg • PO BID • Amovicillin 500 •	Second-line Cephalexin 500 mg PO BID Clindamycin 300 mg	Duration 10 days
Pathogens Group A streptococcus	First-Line Penicillin 500 mg PO BID Amoxicillin 500 mg PO BID	Second-line Cephalexin 500 mg PO BID Clindamycin 300 mg PO TID	Duration 10 days
Pathogens Group A streptococcus Urinary Tract Inf Pathogens	First-Line Penicillin 500 mg PO BID Amoxicillin 500 mg PO BID ection, uncomplicated First-Line	Second-line Cephalexin 500 mg PO BID Clindamycin 300 mg PO TID Second-line	Duration 10 days Duration
Pathogens Group A streptococcus Urinary Tract Inf Pathogens E. coli, Klebsiella, Proteus	First-Line Periciliin 500 mg • PO BID Amoxiciliin 500 mg PO BID ection, uncomplicated First-Line • Nitrofurantoin 100 mg PO q 12 h (only for females, CrCl > 30 ml/min)	Second-line Cephalexin 500 mg PO BID Clindamycin 300 mg PO TID Second-line • Cephalexin 500 mg PO q 12 h • Trimethoprim/ sulfamethoxazole 1 DS tablet PO q12h • Ciprofloxacin 500 mg PO q 12 h	Duration 10 days Duration • Nitrofurantoin x 5 days • Cephalexin x 7 days • TMP/SMX x 3 day • Cipro x 3 days
Pathogens Group A streptococcus Urinary Tract Inf Pathogens E. coli, Klebsiella, Proteus	First-Line Periciliin 500 mg PO BID Amoxiciliin 500 mg PO BID ection, uncomplicated First-Line Nitrofurantoin 100 mg PO q 12 h (only for females, CrCl > 30 ml/min) complicated UTI	Second-line Cephalexin 500 mg PO BID Clindamycin 300 mg PO TID Second-line • Cephalexin 500 mg PO q 12 h • Trimethoprim/ sulfamethoxazole 1 DS tablet PO q12h • Ciprofloxacin 500 mg PO q 12 h	Duration 10 days Duration • Nitrofurantoin x 5 days • Cephalexin x 7 days • TMP/SMX x 3 day • Cipro x 3 days
Pathogens Group A streptococcus Urinary Tract Inf Pathogens E. coli, Klebsiello, Proteus Pyelonephritis, Pathogens	First-Line Pericilii S00 mg • PO BID Amoxicilii S00 mg PO BID ection, uncomplicated First-Line • Nitrofurantoin 100 mg PO q 12 h (only for females, CrCl > 30 ml/min) complicated UT1 First-Line • Restrim 100	Second-line Cephalexin 500 mg PO BID Clindamycin 300 mg PO TID Second-line • Cephalexin 500 mg PO q 12 h • Trimethoprim/ sulfamethoxazole 1 DS tablet PO q12h • Ciprofloxacin 500 mg PO q 12 h	Duration 10 days Duration • Nitrofurantoin x 5 days • Cephalexin x 7 days • TMP/SMX x 3 day • Cipro x 3 days Duration

Fig. 1. Example pocket reference cards. Note. MRSA, methicillin-resistant Staphylococcus aureus; UTI, urinary tract infection; AE-COPD, acute exacerbation of chronic obstructive pulmonary disease; TMP, trimethoprim.

Example of provider feedback

Hello [Provider Name],

This is your biweekly report feedback for ID stewardship in the FM clinic, [date range]. Great job prescribing appropriate antibiotic therapy for otitis media (MRN # XX) by using watch and wait prior to prescribing the antibiotic. Regarding treatment of UTI in pregnancy (MRN # XX), nitrofurantoin is still the first-line treatment for UTI in early pregnancy; however, when cephalexin is used, consider decreasing dosing frequency to just twice daily. Regarding prescribing when there is doubt of infectious cellulitis (MRN # XX), consider asking patient to call clinic if symptoms worsen and then prescribe the antibiotic. You could also consider prescribing a topical over an oral antibiotic. Please let us know what questions you may have.

- FM Stewardship Team

Fig. 2. Example of provider feedback. Note. ID, infectious disease; FM, family medicine; MRN, medical record number; UTI, urinary tract infection.

Study end points

The primary end point of the study was total guideline-concordant antibiotic prescribing. Guideline concordance was determined by the health system's local outpatient ASP guidelines. The prescription regimen was considered guideline concordant if all of the following criteria were met: treatment was indicated and the drug choice, dose, and duration of therapy were each appropriate. Treatment was indicated for UTI only if the patient was symptomatic or was pregnant with bacteriuria regardless of symptoms. Definitions of treatment indicated for both URIs and SSTIs followed national guideline recommendations and were outlined in the institution's guidelines and summarized on pocket cards utilized for provider baseline education. Antibiotics prescribed for URI where a likely viral diagnosis was considered or noted



Fig. 3. Study flowchart. Note. ASP, antimicrobial stewardship program; URI, upper respiratory infection; UTI, urinary tract infection; SSTI, skin and soft-tissue infection.

(eg, bronchitis, viral URI) were considered not indicated. Antibiotics prescribed to patients not meeting the CDC diagnostic criteria for bacterial sinusitis were also considered not indicated as well. Antibiotics prescribed for patients with SSTI with noted welldrained abscesses without surrounding cellulitis or documented "infection unlikely" were considered not indicated.

Statistical analysis

All statistical analyses were performed using SPPS version 22 software (IBM, Armonk, NY). Descriptive statistics were used to present demographic information. Categorical variables are presented as numbers and percentages. To compare the primary end point of total guideline-concordant antibiotic prescribing between the pre-ASP and post-ASP groups, the χ^2 test was performed. Secondary end points collected as categorical data were analyzed using the χ^2 test or the Fisher exact test as appropriate. The Student *t* test was performed to compare interval data, including duration of therapy prescribed in the pre-ASP and ASP groups.

Results

Patient and prescribing demographics

In total, 1,397 antibiotic prescriptions were issued over the 12-month study period (Fig. 3). Patient demographics were similar



Fig. 4. Appropriateness of all antibiotics. Note. ASP, antimicrobial stewardship program.

between groups including sex (pre-ASP 75.6% female vs ASP 73.3% female; P = .663) and average age (pre-ASP 40.8 years ± 20.1 vs ASP 39.8 years ± 23.1; P = .719). Most antibiotic prescriptions (64%) were ordered by third-year medical residents, followed by attending physicians (15%), second-year medical residents (13%), and first-year medical residents (8%).

Baseline prescribing characteristics

In total, 698 antibiotic prescriptions were issued during the 6-month pre-ASP period. The most common indications were URIs (24%), SSTIs (20%), and UTIs (19%). A sample of prescriptions from a randomly generated list of each indication was assessed by the AMCP to establish guideline-concordant antibiotic prescribing at baseline (URIs, n = 30; SSTIs, n = 30; UTIs, n = 30). Total guideline-concordant antibiotic prescribing at baseline was 38.9% for URIs, SSTIs, and UTIs. Of the 30 prescriptions evaluated for URIs, 16 (53.3%) met the criteria for total guideline-concordant prescribing: indicated, 90%; appropriate drug, 76.7%; appropriate dose, 73.3%; and appropriate duration, 80%. The median duration of therapy was 7 days (interquartile range [IQR], 5-10). Of the 30 prescriptions evaluated for SSTI, 5 (16.7%) met the criteria for total guideline-concordant prescribing: indicated, 86.7%; appropriate drug, 56.7%; appropriate dose, 63.3%; and appropriate duration, 73.3%. The median duration of therapy for SSTI was 7 days (IQR, 7-10). Of the 30 prescriptions audited at baseline for UTI, 14 (46.7%) met the criteria for total guideline-concordant prescribing: appropriate drug, 73.3%; appropriate dose, 93.3%; appropriate duration, 66.7%. The median duration of therapy was 7 days (IQR, 5-7). One patient (3.3%) had no recorded urinary symptoms and therefore did not meet the criteria for UTI treatment.

Postintervention guideline-concordant prescribing

During the 6-month intervention period, 699 antibiotic prescriptions were issued with 435 prescriptions eligible for audit and feedback by the AMCP: URI, 183; SSTI, 125; and UTI, 127. Total guideline-concordant prescribing improved to 57.9% (P = .002). Additionally, significant improvement was observed across the total population in guideline-concordant antibiotic selection (pre-ASP 68.9% vs ASP 80.2%, P = .018), dose (pre-ASP 76.7% vs ASP 86.2%; P = .023), and duration of therapy (pre-ASP 73.3% vs ASP 86.2%; P = .02) (Fig. 4). Changes in guidelineconcordant prescribing for individual disease states are shown in Figure 5. There were no significant differences in guidelineconcordant prescribing based on provider type. Data were also 719

analyzed by monthly intervals during the 6-month intervention period, demonstrating significant improvement in total guideline-concordant prescribing over time (P = .001) (Fig. 6).

Changes in antibiotic agent prescribed

Significant changes in the agents prescribed were observed across all 3 infection types. For URI indications, amoxicillin moved to the primary agent prescribed (pre-ASP 25.9% vs ASP 41.8%), and azithromycin prescribing decreased from 25.9% to 18.5% (P = .044). For SSTI indications, cephalexin moved to the primary agent prescribed between groups (pre-ASP 10% vs ASP 31.2%), and the use of sulfamethoxazole/trimethoprim (30% vs 19.2%) and clindamycin (10% vs 1.6%) decreased (P = .01). The use of ciprofloxacin for UTI decreased between study groups (pre-ASP 16.7% vs ASP 3.1%) as well as sulfamethoxazole/trimethoprim (pre-ASP 23.3% vs ASP 14.2%), while nitrofurantoin use increased from 33.3% to 53.5% (P = .020). The median duration of therapy for URI was similar to baseline at 7 days (IQR, 5–7 days, P = .372), while median duration of therapy for UTI decreased to 5 days (IQR, 5-7; P = .098). Prescribed duration of therapy was significantly shorter in the ASP group for SSTI (median, 7 days; IQR, 5-7 days; P = .008).

Discussion

Our findings demonstrate significant improvement in guidelineconcordant antibiotic prescribing for the treatment of URIs, SSTIs, and UTIs following the implementation of an AMCP-led, multifaceted, ASP intervention within an FMRC. This study also adds to the growing body of evidence showing the importance of ASP interventions involving physician residents to establish good prescribing habits early in practice.^{15,17,18} Furthermore, these results support the finding that syndrome-specific interventions are successful in improving antibiotic prescribing in the outpatient setting.¹⁹ Previous studies evaluating multifaceted approaches to implementing ASPs in outpatient settings have also demonstrated success when targeting syndrome-specific prescribing by combining educational interventions with EHR optimization and peer-to-peer comparison.²⁰⁻²³

As of January 2020, The Joint Commission requires all accredited ambulatory health organizations to implement ASPs.²⁴ Our study findings demonstrate that the new elements of performance are measurable and achievable when given adequate resources. Marcelin et al²⁵ proposed framework for outpatient stewardship, called C-DIFF (ie, collaboration/communication, data, interventions, feedback, and follow-up) highlights the significant role of pharmacists in outpatient stewardship and provides a process that outpatient stewardship teams can utilize to implement a successful ASP. A study by Craddock et al9 demonstrated the impact of pharmacist-led, education-only, interventions that targeted both prescribers and patients with viral acute URI in the ambulatory care setting. These researchers found a significant reduction in inappropriate antibiotic prescribing after implementation of the intervention (17.2% vs 13.1%; P = .02). Although their stewardship team included AMCPs and trainees, the interventions were led by an ID-trained pharmacist. Wattengel et al¹⁰ also found that an ID pharmacist performing off-site postprescription audit and feedback in the outpatient setting reduced 30-day treatment failure (5% vs 28%; P < .001) and readmission rates (07% vs 11%; P = .001) when pharmacist interventions were accepted.¹⁰ Our study furthers the evidence that a clinical pharmacist can serve as an ASP leader in the outpatient setting. Importantly,



Appropriateness by Infection Type

Fig. 5. Appropriateness of antibiotics by infection type. Note. ASP, antimicrobial stewardship program; URI, upper respiratory infection; UTI, urinary tract infection; SSTI, skin and soft-tissue infection. Indication: Whether or not antibiotic treatment was indicated. Dose: strength and frequency of antibiotic administration. Regimen: total guideline-concordance (indication, drug, dose, and duration are all appropriate).



Total Guideline-Concordant Prescribing by Month

Fig. 6. Percentage of total guideline-concordant regimen prescribing by month. Indication: Whether or not antibiotic treatment was indicated. Dose: strength and frequency of antibiotic administration. Regimen: total guideline-concordance (indication, drug, dose, and duration are all appropriate).

our intervention was led by an AMCP working directly with the primary-care medical staff. Although the institution's antimicrobial stewardship pharmacist and physician collaborated with the AMCP to develop the outpatient program plan, assess baseline data, provide live education, and be available for questions, the biweekly feedback intervention relied solely on the AMCP. Only 1 other study has been published that highlights the impact of a non-ID-trained AMCP in antibiotic stewardship. Our organization previously piloted a similar audit-and-feedback intervention within a single family medicine primary care office led by the site's AMCP with support of the local stewardship team.¹⁶ Similar to our findings, an improvement in prescribed guideline-appropriate agent and duration of therapy were seen for UTIs and URIs. We chose to build on this intervention within the FMRC by further including SSTI evaluation as well as evaluating appropriate indication and dosing for all disease states.

This study has several limitations. Ambulatory care practice sites will require a certain amount of resources to meet these updated standards, including a leader with adequate time that can be dedicated to ASP activities. These activities include initial provider education, audit-and-feedback interventions, and data analysis. Although this study included a pharmacist with that protected time and the opportunity to audit and provide feedback for every antibiotic prescribed within a 6-month period, it may be unrealistic to expect that other practice sites can perform these activities to the same level. We recommend that an AMCP partner with the local antimicrobial stewardship team to evaluate opportunities to optimize the level of outpatient antimicrobial stewardship that is manageable for the institution's available resources. We did not provide feedback with a quantitative score or peer comparison because we felt that this approach would not be the most conducive to the teaching and learning style or culture of the FMRC. Our study demonstrated that an AMCP can still significantly impact stewardship outcomes without quantitative feedback. The current study included typical limitations of a retrospective study; we relied on appropriate documentation of patient assessment and plan in the EHR to determine appropriateness during audit. We were unable to capture when providers utilized a watch-and-wait strategy throughout this study because cases eligible for audit and feedback were identified via a report of antibiotics prescribed and not a report of diagnoses during the study periods. Thus, we may have underestimated the impact of the intervention. Finally, we did not determine whether there were sustained outcomes (ie, a 6-month postintervention audit); however, ongoing education will always be needed with new residents entering the FMRC annually.

Despite these limitations, this study provides important evidence demonstrating the impact of AMCPs as antimicrobial stewardship leaders in primary care. Further studies are needed to determine whether alternate methods of audit and feedback can decrease workload and still achieve success with guidelineconcordance prescribing habits. Further studies could also evaluate methods of real-time recommendations by an AMCP or EHR order sets developed from the institution's guidelines that are maintained and updated by an AMCP. In summary, AMCP-led audit-and-feedback within a FMRC significantly improved guideline-concordant antibiotic prescribing for common infection types. AMCPs can serve as key leaders in implementing successful outpatient antimicrobial stewardship interventions. As resources for outpatient efforts are often scarce, ASPs looking to expand to outpatient settings should evaluate opportunities to collaborate with AMCPs to implement sustainable interventions promoting optimal prescribing.

Acknowledgments. 1) Lindsey Westerhof was affiliated with Ferris State University College of Pharmacy in Grand Rapids, MI during the time of study protocol development and data collection. Data analysis, presentation and manuscript preparation were completed while affiliated with Mercy Health Saint Mary's.

2) We'd like to thank the Wege Family Medicine Residency Clinic for graciously collaborating on this quality improvement project.

Financial support. No financial support was provided relevant to this article.

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

References

- 1. Centers for Disease Control and Prevention. *Outpatient antibiotic prescriptions—United States*, 2018. Atlanta, GA: CDC; 2018.
- Fleming-Dutra K, Hersch A, Shapiro D, *et al.* Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010–2011. *JAMA* 2016;315:1864–1873.
- 3. US National action plan for combating antibiotic-resistant bacteria, 2015. The White House website. https://obamawhitehouse.archives.gov/sites/ default/files/docs/national_action_plan_for_combating_antibotic-resistant_ bacteria.pdf. Published 2015. Accessed October 23, 2020.
- Durkin, MJ, Jafarzadeh SR, Hsueh K, *et al.* Outpatient antibiotic prescription trends in the United States: a national cohort study. *Infect Control Hosp Epidemiol* 2018;39:584–589.
- Barlam T, Cosgrove S, Abbo L, et al. Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of America and the society for healthcare epidemiology of America. Clin Infect Dis 2016;62:51–77.
- Sanchez G, Fleming-Dutra K, Roberts R, Hicks L. Core elements of outpatient antibiotic stewardship. MMWR Recomm Rep 2016;65(6):1–12. doi: 10.15585/mmwr.rr6506a1
- Blanchette, L, Gauthier T, Heil E, et al. The essential role of pharmacists in antibiotic stewardship in outpatient care: an official position statement of the society of infectious diseases pharmacists. J Am Pharm Assoc 2018;58:481–484.
- Eppert H, Rezneck A. ASHP guidelines on emergency medicine pharmacist services. Am J Health-Syst Pharm 2011;68:81–95.
- ASHP statement on the pharmacist's role in antimicrobial stewardship and infection prevention and control. Am J Health-Syst Pharm. 2010;67: 575-577. doi: 10.2146/sp100001
- Wattengel BA, Sellick JA, Mergenhagen KA. Outpatient antimicrobial stewardship: optimizing patient care via pharmacist led microbiology review. Am J Infect Control 2020;48:189–193.

- 11. Craddock K, Molino S, Stranges P, et al. The impact of educational interventions on antibiotic prescribing for acute upper respiratory tract infections in the ambulatory care setting: a quasi-experimental study. J Am Coll Clin Pharm 2020;3:609–614.
- Gerber JS, Prasad PA, Fiks AG, *et al.* Effect of an outpatient antimicrobial stewardship intervention on broad-spectrum antibiotic prescribing by primary care pediatricians: a randomized trial. *JAMA* 2013;309: 2345–2352.
- McCormick JZ, Cardwell SM, Wheelock C, *et al.* Impact of ambulatory antimicrobial stewardship on prescribing patterns for urinary tract infections. *J Clin Pharm Ther* 2020. doi: 10.1111/jcpt.13210.
- Eudaley ST, Mihm AE, Higdon R, *et al.* Development and implementation of a clinical decision support tool for treatment of uncomplicated urinary tract infections in a family medicine resident clinic. *J Am Pharm Assoc* 2019;59:579–585.
- Van Langen KM, Dumkow LE, Axford KL, et al. Evaluation of a multifaceted approach to antimicrobial stewardship education methods for medical residents. *Infect Control Hosp Epidemiol* 2019;40:1236–1241.
- Burns KW, Johnson KM, Pham SN, et al. Implementing outpatient antimicrobial stewardship in a primary care office through ambulatory care pharmacist-led audit and feedback. J Am Pharm Asso. 2020. doi: 10.1016/j. japh.2020.08.003.
- Davey P, Garner S. Professional education on antimicrobial prescribing: a report from the specialist advisory committee on antimicrobial resistance (SACAR). J Antimicrob Chemother 2007;60 suppl 1:i27-i32.
- Pulcini c, Gyssen IC. How to educate prescribers in antimicrobial stewardship practices. Virulence 2013;4:192–202.
- Pollack LA, Srinivasan A. Core elements of hospital antibiotic stewardship programs from the Centers for Disease Control and Prevention. *Clin Infect Dis* 2014;59 suppl 3:S97–100.
- 20. Buehrle DJ, Shively NR, Wagener MM. Sustained reductions in overall and unnecessary antibiotic prescribing at primary care clinics in a Veterans' Affairs Healthcare System following a multi-faceted stewardship intervention. *Clin Infect Dis* 2019. doi: 10.1093/cid/ciz1180.
- 21. Gulliford MC, Prevost AT, Charlton J, et al. Effectiveness and safety of electronically delivered prescribing feedback and decision support on antibiotic use for respiratory illness in primary care: REDUCE cluster randomised trial. *BMJ* 2019;364:1236.
- 22. Penalva G, Fernandez-Urrusuno R, Turmo JM, *et al.* Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum β-lactamase-producing Escherichia coli in the community: an interrupted time-series analysis. *Lancet Infect Dis* 2020;20:199–207.
- 23. Peterson E, Fergus J, Yost C, et al. The effect of a multimodal stewardship approach on antibiotic prescribing for outpatients with acute respiratory tract infections: order set implementation and education. J Am Coll Clin Pharm 2020. doi: 10.1002/jac5.1303.
- 24. The Joint Commission. Antimicrobial stewardship in ambulatory health care. R3 Report 2019;23:1–3.
- Marcelin JR, Chung PC, Van Schooneveld TC. Antimicrobial stewardship in the outpatient setting: A review and proposed framework. *Infect Control Hosp Epidemiol* 2020. doi: 10.1017/ice.2020.94.